Search research articles
Contact Us
Filters
Showing results (151-160 of 179) with videos related to
Page
of 18
Sort By:
Neuro-Oncology Advances
|
July 16, 2020
Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma
Stephanie Vairy, Gwénaël Le Teuff, Francisco Bautista, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 14, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Leo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal for Immunotherapy of Cancer
|
September 2, 2022
Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma
Ana Costa, Cécile Thirant, Amira Kramdi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2025
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Leo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Leo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Expert Opinion on Drug Discovery
|
June 13, 2017
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project
Lucas Moreno, Hubert Caron, Birgit Geoerger, et al.
Cancer Discovery
|
March 16, 2022
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies
Pablo Berlanga, Gaelle Pierron, Ludovic Lacroix, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia
Anouchka P Laurent, Aurélie Siret, Cathy Ignacimouttou, et al.
Nature Communications
|
May 4, 2023
Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma
Cécile Thirant, Agathe Peltier, Simon Durand, et al.
Nature Genetics
|
July 26, 2017
Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries
Valentina Boeva, Caroline Louis-Brennetot, Agathe Peltier, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 179) with videos related to
Sort By:
Page
of 18
Neuro-Oncology Advances
|
July 16, 2020
Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma
Stephanie Vairy, Gwénaël Le Teuff, Francisco Bautista, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 14, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Leo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal for Immunotherapy of Cancer
|
September 2, 2022
Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma
Ana Costa, Cécile Thirant, Amira Kramdi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2025
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Leo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Leo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Expert Opinion on Drug Discovery
|
June 13, 2017
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project
Lucas Moreno, Hubert Caron, Birgit Geoerger, et al.
Cancer Discovery
|
March 16, 2022
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies
Pablo Berlanga, Gaelle Pierron, Ludovic Lacroix, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia
Anouchka P Laurent, Aurélie Siret, Cathy Ignacimouttou, et al.
Nature Communications
|
May 4, 2023
Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma
Cécile Thirant, Agathe Peltier, Simon Durand, et al.
Nature Genetics
|
July 26, 2017
Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries
Valentina Boeva, Caroline Louis-Brennetot, Agathe Peltier, et al.
Page
of 18